Plain-English translation of NCT07303686 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This pilot study is testing whether patients with Crohn's disease or ulcerative colitis who are in remission (doing well) can safely reduce their dose of ustekinumab. The study will compare two different dosing schedules of this medication over 12 months to see if a lower dose can work just as well while potentially reducing side effects and costs.
Many patients on this medication do very well and stay in remission, but taking high doses long-term can increase the risk of side effects and financial burden. Researchers want to know if patients who are stable and in remission can safely use lower doses without their disease flaring back up.
You likely qualify if…
You likely don't qualify if…
You will be in this study for 12 months and will visit the clinic 4–6 times. During the study, you will continue taking the medication, but you may receive it at a lower dose than you currently take. The research team will monitor your health through visits, blood tests, and possibly exams to make sure you remain in remission and that the lower dose is working well for you.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Canada